Suman Sen

Suman Sen

Novartis Institutes for BioMedical Research - Bhubaneswar / United States
Natural Sciences / Mathematical Sciences
AD Scientific Index ID: 4382950
-
person_outline Suman Sen's MOST POPULAR ARTICLES
1-) Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinomaM Javle, M Lowery, RT Shroff, KH Weiss, C Springfeld, MJ Borad, ...Journal of Clinical Oncology 36 (3), 276, 20185312018
2-) Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumorsJR Infante, EC Dees, AJ Olszanski, SV Dhuria, S Sen, S Cameron, ...Journal of clinical oncology 32 (28), 3103-3110, 20141602014
3-) A Phase IB multicentre dose‐determination study of BHQ 880 in combination with anti‐myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma …SP Iyer, JT Beck, AK Stewart, J Shah, KR Kelly, R Isaacs, S Bilic, S Sen, ...British journal of haematology 167 (3), 366-375, 20141492014
4-) Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumorsLV Sequist, P Cassier, A Varga, J Tabernero, JH Schellens, JP Delord, ...Cancer Research 74 (19 Supplement), CT326-CT326, 20141022014
5-) A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.MM Javle, RT Shroff, A Zhu, S Sadeghi, SP Choo, MJ Borad, MA Lowery, ...Journal of Clinical Oncology 34 (4_suppl), 335-335, 2016742016